Mash - Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials
4 recruiting trials for Mash - Metabolic Dysfunction-Associated Steatohepatitis. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Mash - Metabolic Dysfunction-Associated Steatohepatitis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2: 1.
Research is led by E-Scopics (1), Akero Therapeutics, Inc (1), Yale University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Placebo (drug, 2 trials), followed by Liver ultrasound, Efruxifermin.
Track Mash - Metabolic Dysfunction-Associated Steatohepatitis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with...
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was...
Rezdiffra Pregnancy and Lactation Registry
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Mash - Metabolic Dysfunction-Associated Steatohepatitis, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Mash - Metabolic Dysfunction-Associated Steatohepatitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Mash - Metabolic Dysfunction-Associated Steatohepatitis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.